|Articles|October 28, 2004

ITF_milken

Pharmaceutical science and technology news

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related to this article

Blue medical pens for glp-1 semaglutide therapy on a white background for illustrating diabetes control and morbid obesity treatment. | Image credit: © Shutterly - © Shutterly - stock.adobe.com

September 15th, 2026

The Shift From Intravenous to Subcutaneous Biologics in 2026

2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.

ITF_milken

Related to this article

Trending on Pharmaceutical Technology

PharmTech Weekly Roundup—September 18, 2026

Introducing the "PharmTech AI Pulse Check" Expert Video Series

Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response

Can AI Agents Satisfy CGMP Documentation Requirements?

Lessons For AI Governance in Quality Systems